Bristol Myers Squibb (BMY) Cash from Operations (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Cash from Operations for 18 consecutive years, with $3.4 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations fell 13.38% year-over-year to $3.4 billion in Q2 2026; TTM through Jun 2026 was $12.8 billion, a 19.62% decrease from a year earlier, with the FY2025 full-year figure at $14.2 billion, down 6.81% from the prior year.
• Cash from Operations was $3.4 billion for Q2 2026 at Bristol Myers Squibb, up from $1.1 billion in the prior quarter.
• Over five years, Cash from Operations peaked at $6.3 billion in Q3 2025 and troughed at $1.1 billion in Q1 2026.
• A 5-year average of $3.4 billion and a median of $3.3 billion in 2022 frame the typical range for Cash from Operations.
• The widest YoY moves for Cash from Operations: up 68.4% in 2025, down 55.53% in 2025.
• Over 5 years, Cash from Operations stood at $3.3 billion in 2022, then advanced by 28.61% to $4.3 billion in 2023, then rose by 4.4% to $4.4 billion in 2024, then sank by 55.53% to $2.0 billion in 2025, then soared by 71.88% to $3.4 billion in 2026.
• The last three Cash from Operations figures came in at $3.4 billion (Q2 2026), $1.1 billion (Q1 2026), and $2.0 billion (Q4 2025), per Business Quant data.